Compare NPV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPV | ARMP |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.3M | 199.7M |
| IPO Year | 1995 | 1996 |
| Metric | NPV | ARMP |
|---|---|---|
| Price | $9.48 | $3.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 120.9K | ★ 271.5K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.05 | $3.14 |
| 52 Week High | $11.81 | $14.98 |
| Indicator | NPV | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 39.97 |
| Support Level | $9.05 | $3.38 |
| Resistance Level | $11.61 | $5.63 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 59.98 | 29.69 |
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.